Faverio, 901 patient N-acetylcysteine late treatment study: 19% higher mortality [p=0.33], 34% higher ICU admission [p=0.08], and 1% higher hospital discharge [p=0.94] https://c19p.org/faverio
copied to clipboard
Impact of N-acetyl-l-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study
et al., ERJ Open Research, doi:10.1183/23120541.00542-2021, STORM, NCT04424992 (history)
Retrospective 1,083 consecutive hospitalized COVID patients in Italy, showing no significant differences with NAC treatment. The number of patients transferred to another facility exceeds the number of deaths, which may significantly affect results.
|
risk of death, 19.0% higher, RR 1.19, p = 0.33, treatment 91 of 572 (15.9%), control 44 of 329 (13.4%), propensity score weighting.
|
|
risk of ICU admission, 33.8% higher, RR 1.34, p = 0.08, treatment 107 of 572 (18.7%), control 46 of 329 (14.0%), propensity score weighting.
|
|
risk of no hospital discharge, 1.4% lower, RR 0.99, p = 0.94, treatment 180 of 572 (31.5%), control 105 of 329 (31.9%), NNT 224, propensity score weighting.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Faverio et al., 2 Dec 2021, retrospective, Italy, peer-reviewed, 10 authors, study period February 2020 - April 2021, trial NCT04424992 (history) (STORM).
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.